306 results about "Bacillus perfringens" patented technology

The present invention demonstrated the potential use of Lactobacillus johnsonii D115 as a probiotic, as a prophylactic agent or as a surface treatment of materials against human and animal pathogens such as Brachyspira pilosicoli, Brachyspira hyodysenteriae, Shigella sonnei, Vibrio cholera, Vibrio parahaemolyticus, Campylobacter jejuni, Streptococcus pneumoniae, Enterococcus faecalis, Enterococcus faecium, Clostridium perfringens, Yersinia enterocolitica, Escherichia coli, Klebbsiella pneumoniae, Staphylococcus aureus, Salmonella spp., Bacillus cereus, Aspergillus niger and Fusarium chlamydosporum. The proteineous antimicrobial compound was partially characterized and found to be heat tolerant up to 121° C. for 15 min, and acid tolerant up to pH1 for 30 min at 40° C. The compound is also stable to enzymatic digestion, being able to retain more than 60% antimicrobial activity when treated with pepsin and trypsin.

Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens. A novel strain of Bacillus subtilis was isolated from the gastrointestinal tract of poultry and was found to produce a factor or factors that have excellent inhibitory effects on Clostridium perfringens, Clostridium difficile, Campylobacter jejuni, Campylobacter coli, and Streptococcus pneumoniae. The factor(s) retain full viability and antimicrobial activity after heat treatment. The invention provides a method of treatment of pathogenic microorganisms including C. perfringens.

Gene expression profiling and hierarchial clustering analysis readily distinguish normal ovarian epithelial cells from primary ovarian serous papillary carcinomas. Laminin, tumor-associated calcium signal transducer 1 and 2 (TROP-1 / Ep-CAM; TROP-2), claudin 3, claudin 4, ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, osteopontin, kallikrein 6 (protease M), kallikrein 10, matriptase and stratifin were found among the most highly overexpressed genes in ovarian serous papillary carcinomas, whereas transforming growth factor beta receptor III, platelet-derived growth factor receptor alpha, SEMACAP3, ras homolog gene family, member I (ARHI), thrombospondin 2 and disabled-2 / differentially expressed in ovarian carcinoma 2 (Dab2 / DOC2) were significantly down-regulated. Therapeutic strategy targeting TROP-1 / Ep-CAM by monoclonal chimeric / humanized antibodies may be beneficial in patients harboring chemotherapy-resistant ovarian serous papillary carcinomas. Claudin-3 and claudin-4 being receptors for Clostridium Perfringens enterotoxin, this toxin may be used as a novel therapeutic agent to treat ovarian serous papillary tumors.

The invention discloses high levels of receptors for Clostridium perfringens enterotoxin (CPE) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of CPE is disclosed. High levels of Ep-CAM protein is also disclosed in ovarian cancer tissue samples. Thus, the invention provides a method of treating ovarian cancer and uterine cancer by administering CPE. The invention also provides a method of treating cancer in a mammal involving intraperitoneal administration of CPE, where at least some cancerous cells are located in or adjacent to the peritoneal cavity of the mammal. The invention also provides a method of treating ovarian cancer involving administering an anti-Ep-CAM antibody. The invention also provides a method of treating cancers expressing claudin-3 or claudin-4 by administering an antibody against claudin-3 and / or an antibody against claudin-4. The invention also provides a method of protecting a mammal from CPE toxicity involving administering a protective agent that binds to claudin-3 and / or claudin-4 and inhibits CPE binding to claudin-3 and / or claudin-4.

Methods of diagnosis, prognosis, and treatment of breast cancer, and of metastatic brain cancer, are provided The diagnostic and prognostic methods involve the immunohistochemical detection of the level of expression of the proteins claudin 1, 3, 4, and 7 in tissue or cell samples. Claudins 1 and 7 are underexpressed in the majority of breast cancers, and claudins 3 and 4 are overexpressed. The methods of treatment involve the use of Clostridium perfringens enterotoxin (or a variant thereof) to lyse metastatic cancer cells in the brain and bone that overexpress claudins 3 and 4.

The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.

The invention discloses preparation and application of Clostridium butyricum and a live Clostridium butyricum preparation; Clostridium butyricum LXKJ-1 is collected in China Center for Type Culture Collection on 24 March, 2016 under CCTCC NO: M201613. A seed medium, fermentation medium formulation, culture conditions for Clostridium butyricum and a production of a preparation of live Clostridium butyricum are also disclosed. The Clostridium butyricum provided herein is tolerant to acids, bases and high temperature, is highly capable of producing butyric acid, can inhibit animal pathogens, such as Escherichia coli, Salmonella, Shigella, Staphylococcus aureus, Listeria monocytogenes, and Clostridium perfringens, and can prevent diarrhea in livestock and poultry due to Escherichia coli, Salmonella and Clostridium perfringens, improving intestinal flora balance, promoting the growth of livestock and poultry, relieving constipation in sows, improving egg weight for layers, improving eggshell quality for layers, and decreasing egg-feed ratio.

The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“C. difficile”), Clostridium perfringens (“C. perfringens”), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.

The invention relates to the field of infant foods and in particular relates to a probiotics composition as well as an application and infant food thereof. The probiotics composition is prepared from bifidobacterium HN019 and lactobacillus rhamnosus HN001. With the adoption of the infant food, the content of the bifidobacterium and the content of the lactobacillus rhamnosus in intestinal canals of infants can be remarkably increased, the content of bacillus perfringens is remarkably lowered, and the micro-ecological environments of the intestinal canals of the infants are effectively improved; the content of acetic acid and the total content of short-chain fatty acid in faeces of the infants can be remarkably increased, and approach to those of the infants fed by pure breast milk; the content of sIgA (secretory immunoglobulin A) in the faeces of the infants can be remarkably increased, and approach to that of the infants fed by pure breast milk; the eczema occurrence rate of the infants can be remarkably lowered.

The present invention provides a gene chip for quickly detecting pathogens from food source, discloses the preparation method of said gene chip and provides 26 oligonucleotide probe sequences for detection. Said gene chip can quickly, accurately and high-effectively detect and identify the class of the pathogens in food, and its detection range includes staphylococcus aureus, Shiga's bacillus, salmonella, colibacillus 0157, bacillus proteus, mononuclear hyperplastic listerella, enterocolitis yersinia, aeruginous pseudomonads, vibrio parahaemolyticus, vibrio cholerae, bacillus cereus, beta hemolytic streptococcus, coconut fermentation pseudomonads, boticin, vibrio jejuni and bacillus perfringens, etc.

The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Clostridium perfringens, and methods of using that bacteriophage, and / or progeny or derivatives derived therefrom, to control the growth of Clostridium perfringens in various settings.

The invention discloses a quadruple fluorescent PCR (Polymerase Chain Reaction) detection kit for common chicken food-borne bacteria and an application method thereof. The kit contains a fluorescent PCR solution and standards of Clostridium perfringens, Salmonella enteritidis, Escherichia coli O157: H7 and Campylobacter jejuni, wherein the fluorescent PCR solution contains Taq DNA (deoxyribonucleic acid) polymerase, a PCR buffer solution, Mg<2+>, dNTPs (deoxy-ribonucleoside triphosphates), four pairs of bacterial specific primers and four kinds of corresponding fluorescent probes. According to the detection kit and the application method thereof, four kinds of chicken-carried main food-borne pathogenic bacteria, namely Clostridium perfringens, Salmonella enteritidis, Escherichia coli O157: H7 and Campylobacter jejuni, can be rapidly and accurately detected by using quadruple fluorescent PCR, and the detection kit can be applied to the assay of bacteria, the diagnosis of diseases and epidemiological investigation.

A Bacillus strain characterized by (i): sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol; (ii) antimicrobial activity against E. coli and Clostridium perfringens; and (iii) a sporulation percentage of at least 80 when measured after 2 days of incubation. The invention further relates to a method for selecting such strains. Many of the identified strains according to the invention are of the species Bacillus amyloliquefaciens. Some of the Bacillus amyloliquefaciens were further identified as Bacillus amyloliquefaciens subsp. amyloliquefaciens whereas others were identified as amyloliquefaciens subsp. plantarum. A Bacillus strain of the invention may be used as a feed additive to animal feed where it has a probiotic effect.

The invention relates to bacillus subtilis BYS2 with high-efficiency antibacterial activity, which has a preservation number of CGMCC NO.14220. The bacillus subtilis BYS2 has the advantages of high temperature resistance, acid resistance and cholate resistance; the bacillus subtilis BYS2 can adapt to the gastrointestinal environment and has significant inhibitory effects on escherichia coli, staphylococcus aureus and clostridium perfringens; the bacillus subtilis BYS2, as a feed additive, has the advantages that the ability (p is smaller than 0.05) of animal body to resist infection of pathogenic microorganisms can be improved, the growth performance of broilers is significantly promoted and breeding benefits are improved; meanwhile, the bacillus subtilis BYS2 has the characteristics of safety, high efficiency and probiotic function as well as no toxic or side effects on animal bodies.

Chromogenic 3-Indoxyl choline phosphate compounds of formula (I):wherein R is selected from the group consisting of hydrogen and C1-4 alkyl, such as methyl, ethyl, propyl and butyl while R<1>, R<2>, R<3>, and R<4 >are independently selected from the group consisting of hydrogen, halogen, cyano, nitro, carboxy, amino, amino substituted with one or two C1-4 alkyl groups, aminomethyl, hydroxy, C1-4 alkoxy, carboxyalkyl, and sulphonyl. These compounds are capable of being cleaved by lecithinase C leading to products which are calorimetrically detectable. The invention provides safe and sensitive detection of potentially pathogenic bacterial activity of such microbes as Clostridium perfringens, Bacillus cereus, Bacillus anthracis, Pseudomonas aeruginosa, Listeria monocytogenes, Heliobacter pylori, Legionella pneumophila, and others in material which may contain such activity typically including physiological samples, goods for consumption, such as food and beverages, and any other potentially infected objects or articles.

A nucleic acid comprising a nucleotide sequence encoding a lysin, which nucleotide sequence comprises the sequence shown in SEQ IDNo. 1 or a variant, homologue or derivative thereof. A novel lysin obtainable from a bacteriophage capable of colonising Clostridium perfringens, and the use thereof as a medicament for the treatment of a disorder associated with pathogenic Clostridium bacteria, for example.

The invention provides a new strain FM 603 of bacillus coagulans, and the preservation number of the strain is CGMCC NO.10221. The strain can generate bacteriocin antibacterial substances and achieves antibacterial activity for Gram-positive pathogenic bacteria such as Listeria monocytogenes, staphylococcus aureus, methicillin-resistant staphylococcus aureus, clostridium perfringens and clostridium difficile. The molecular weight of bacteriocin is 4276.45 Da, the partial amino acid sequence is Ala-Gly-His-Dhb-Phe-Val-Dhb-Gly-Pro, and the bacteriocin is stable under treatment of heat, acid, and pepsase or trypsin and can be degraded easily by pronase to be inactivated. The invention further provides an FM603 fermentation product which can be used as a microbiological feed additive. Animal test results show that the fermentation product can increase the laying rate of laying hens, reduce the feed-egg ratio and improve egg quality; the feed intake and daily gain of piglets are increased, and the feed conversion ratio is reduced; the daily gain and the content of lysozyme in serum of broiler chickens are increased, and the feed conversion ratio and the death rate are reduced.

The invention discloses a rabbit triple inactivated vaccine, a preparation method and the application thereof; the rabbit triple inactivated vaccine is formed mainly by rabbit hemorrhagic disease virus liquid which is inactivated and detoxified, rabbit pasteurella multocida liquid and rapid A type clostridium perfringens liquid which have 1:1:2 volume ratio; in the invention, by optimizing culture technology, concentration technology and immunizing dose and other measures, the rabbit triple inactivated vaccine which has good immunity effect and safety is obtained and can effectively control the rabbit hemorrhagic disease, the pasteurella multocida disease and the pasteurella multocida disease (A type) and reduce vaccine injection times of farmers, so as to reduce the stress reaction of animals and improve the production performance. The clinical application proves that the immunization effect of the rabbit triple inactivated vaccine is ideal, each rabbit is vaccinated with 2ml and has immunity after 5-7 days, the immune period is at least 180 days, and the immune safety is good without toxic and side effect.

The invention discloses a fermented dairy product containing a compound prebiotic and probiotic group. Lactobacillus bulgaricus, Streptococcus thermophilus, Bifidobacterium lactis BB-12 and Lactobacillus acidophilus are added into the fermented dairy product. Two kinds of prebiotics, namely fructooligosaccharide and galactooligosacchride are also added into the fermented dairy product; and the content of the fructooligosaccharide is 0.25 to 60g and the content of the galactooligosacchride is 0.25 to 60g in 1,000g of fermented dairy product raw material, and the content sum of the fructooligosaccharide and the galactooligosacchride is 0.5 to 120g. By the fermented dairy product containing the compound prebiotic and probiotic group, the phenomenon that the excessive eating of a fermented dairy product may cause flatulence, exhaust and diarrhea of a small number of users when single prebiotics are used is avoided, and Bifidobacterium and lactobacillus in intestinal tracts have a good proliferation effect; and meanwhile, the fermented dairy product slightly proliferates enterococcus, enterobacter and Clostridium perfringens, and produces low pH values in the intestinal tracts.

The invention discloses a primer, a kit and a method for detecting Pseudomonas aeruginosa and Clostridium perfringens. The primer sequence and probe sequence are respectively: upstream primer P.AF, downstream primer P.AR, probe P .AP, upstream primer C.PF, downstream primer C.PR:, probe C.PP. The purpose of the present invention is to overcome the deficiencies in the prior art, to provide a primer with reasonable components and ratio, easy to use, fast and accurate detection, suitable for double ddPCR detection of Pseudomonas aeruginosa and gas production in water The test kit of Clostridium perfringens; Another purpose of the present invention is to provide a kind of method that adopts above-mentioned test kit to detect Pseudomonas aeruginosa and Clostridium perfringens in water, and this method is easy and simple to operate, fast, and cost is low, and detection result precise.

The invention discloses Bacillus licheniformis H2 which is resistant to acid, heat and cholate and has good resistance to Clostridium perfringens and application of Bacillus licheniformis H2 in prevention and control of necrotic enteritis in chicken. The strain is obtained by separation, screening and identification, and has the preservation number of CCTCC NO: M2011133; and Bacillus licheniformis H2 can be prepared into a microorganism preparation, and can effectively prevent and control necrotic enteritis in chicken caused by Clostridium perfringens, promote growth of normal physiological anaerobic bacteria in intestinal tract of chicken, improve intestinal tract microorganism diversity and immune organ index of chicken and improve growth performance of chicken when used as a veterinary medicine and chicken feed additive. Bacillus licheniformis H2 is suitable for feed factories, veterinary drug factories and scaled chicken farms.

The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Clostridium perfringens, and methods of using that bacteriophage, and / or progeny or derivatives derived therefrom, to control the growth of Clostridium perfringens in various settings.

The invention discloses a detection method for clostridium perfringens, a primer group and a detection kit for same. The primer group is based on the Loop-Mediated Isothermal Amplification (LAMP), and is obtained through analysis, design and artificial synthesis on the special alpha toxin (C. perfringens alpha toxin, CPa) gene sequence of the clostridium perfringens, the contained nucleotide sequence is shown in SEQ No.1-4, and the primer group has considerably high specificity to the clostridium perfringens. The fast detection method for the clostridium perfringens carries out LAMP reaction on the DNA of the clostridium perfringens in a sample by utilizing the detection primer group, and whether the clostridium perfringens is contained in the sample or not is judged by identifying reaction products. The invention also designs the fast detection kit for the clostridium perfringens according to the detection method, so that fast, simple, accurate and efficient clostridium perfringens detection and identification can be carried out on the sample.

The invention discloses bacillus subtilis with an effect of inhibiting clostridium perfringens; the bacterial strain is named the bacillus subtilis BLCC1-0155. The bacillus subtilis BLCC1-0155 disclosed by the invention has a powerful inhibiting effect on the clostridium perfringens, and also has the inhibiting effect on escherichia coli and staphylococcus aureus. Proved by an animal experiment, a microecologics product taking the bacillus subtilis BLCC1-0155 as an effective component is capable of preventing necrotic enteritis of broilers better, therefore the hurt of the necrotic enteritis to intestinal tracts of the broilers is reduced, and the death rate is greatly reduced; meanwhile, the microecologics product is also capable of increasing the daily gain of the broilers, and is a relatively ideal microecologics product, which can be clinically applied, used for preventing the necrotic enteritis of the broilers.

The invention relates to a clostridium perfringens alpha toxin double-antibody sandwich ELIS quantitative determination method. According to the clostridium perfringens alpha toxin double-antibody sandwich ELIS quantitative determination method, alpha toxin protein obtained via prokaryotic expression is taken as an immunogen; monoclonal antibodies obtained via hybridoma technique are taken as detection antibodies and capture antibodies; reaction conditions are optimized via experiments; alpha toxin protein samples with a series of concentration are used for construction of a standard curve; the double-antibody sandwich ELIS method is established; and indexes of the double-antibody sandwich ELIS are verified. The clostridium perfringens alpha toxin double-antibody sandwich ELIS quantitative determination method specifically comprises following steps: (1) prokaryotic expression of alpha toxin; (2) preparation of anti-alpha toxin monoclonal antibodies; (3) establishment of the double-antibody sandwich ELIS method; (4) establishment of the standard curve; and (5) performance evaluation on the double-antibody sandwich ELIS method. The clostridium perfringens alpha toxin double-antibody sandwich ELIS quantitative determination method is excellent in specificity, and high in sensitivity and stability, is fast and convenient, and can be used for effective quantitative determination of alpha toxin in A-E type clostridium perfringens cultural supernatants; and the high-efficient detection method is provided for alpha toxin determination.

The invention relates to the field of animal bacteriology and provides a preparation method of an inactivated vaccine of A-type clostridium perfringens for clostridium welchii disease of a domestic rabbit. The preparation method comprises the following steps: adopting the A-type clostridium perfringens as an original strain, finally obtaining a bacterium solution by primary and secondary culture, mixing the bacterium solution and white oil adjuvant and preparing the inactivated vaccine of the A-type clostridium perfringens. The vaccine prepared by the method is immunized for the domestic rabbit, the protective rate reaches 100% after counteracting toxic substances, so that good immunoprotection action is achieved.

The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.